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specimens have been replaced by automated biuret methods in virtually all routine
clinical testing. A subset of laboratories, however, still report using refractometry to
measure TP in conjunction with serum protein electrophoresis. The objective of this study
was therefore to conduct a modern performance evaluation of a digital refractometer for
TP measurement.
Design and methods: Performance evaluation of a MISCO Palm Abbe™ digital re-
fractometer was conducted through device familiarization, carryover, precision, accuracy,
linearity, analytical sensitivity, analytical specificity, and reference interval verification.
Comparison assays included a manual refractometer and an automated biuret assay.
Results: Carryover risk was eliminated using a demineralized distilled water (ddH2O)
wash step. Precision studies demonstrated overall imprecision of 2.2% CV (low TP pool)
and 0.5% CV (high TP pool). Accuracy studies demonstrated correlation to both manual
refractometry and the biuret method. An overall positive bias (þ5.0%) was observed
versus the biuret method. On average, outlier specimens had an increased triglyceride
concentration. Linearity was verified using mixed dilutions of: a) low and high con-
centration patient pools, or b) albumin-spiked ddH2O and high concentration patient pool.
Decreased recovery was observed using ddH2O dilutions at low TP concentrations. Sig-
nificant interference was detected at high concentrations of glucose (4267 mg/dL) and
triglycerides (4580 mg/dL). Current laboratory reference intervals for TP were verified.
Conclusions: Performance characteristics of this digital refractometer were validated in a
clinical laboratory setting. Biuret method remains the preferred assay for TP measurement
in routine clinical analyses.
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Refractometry has been used for over 100 years to measure the density of biological solutions. Refraction is the
change in direction of a light wave as it passes through the boundary of two mediums with different wave propagation
speeds. The ratio of the wave speed in air versus its speed in another medium (e.g. water) is known as its refractive
index. Refractometry has been particularly valuable in assessing urine concentrations through specific gravity (SG)
measurements [1].
Refractometry has also been used in the assessment of serum and/or plasma total protein (TP) measurements [2–5]. In
this capacity, refractometer scales are calibrated against normal serum, with the general assumption that many non-protein
solutes (e.g. electrolytes) are at similar, relatively low concentrations across patient specimens [6]. Many substances do,
however, vary significantly between individuals (e.g. lipids), and this may alter solution density such that refractometric
assessment of TP may be innaccurate [7]. While handheld manual refractometers (developed in the 1960s) provided a rapid
and accessible method for TP measurement, modern clinical chemistry analyzers now provide more sensitive, specific, and
automated measurements of TP primarily through the biuret method [8]. Refractometry has therefore become regarded as a
less acceptable technique for routine human serum or plasma TP measurement [9].
While “refractometer” remains an available TP method selection in the College of American Pathologists (CAP) General
Chemistry and Therapeutic Drugs proficiency testing (PT) surveys [10], the overwhelming number of participant labora-
tories (99.6%) use automated biuret-based methods for TP measurement [11]. Refractometry-based TP measurement still
maintains a presence, however, in select applications such as serum protein electrophoresis. For example, 2.4% (n¼20 of
842) participants in a recent CAP Electrophoresis PT survey used refractometry to determine TP concentration [12]. Pre-
sumably, these laboratories select refractometry for the convenience of rapid, inexpensive TP testing in close proximity to
specialized electrophoresis instrumentation. While manual and digital refractometry is also used extensively in veterinary
medicine for assessing TP, immunoglobulin G, and dissolved solid concentrations in serum, plasma, and colostrum [13–21],
few studies have focused on the potential application of digital refractometry in modern analytical settings [22].
In a companion study to the present report [23] we conducted a clinical validation of a handheld digital refractometer to
serve as a replacement for manual urine SG measurements in our laboratory. As a human blood (serum/plasma) TP scale
was also available on this handheld device, we conducted the present experiments to: a) evaluate the performance of a
digital refractometer versus a manual refractometer and a biuret method of TP measurement, and b) to investigate the
potential for non-protein substances to interfere with TP measurement when using refractometry. By using a digital re-
fractometer we excluded any contribution of subjective operator interpretation of a visual TP scale.2. Materials and methods
A Palm Abbe™model PA202X (MISCO; Solon, OH) was used as the digital refractometer for all experiments. The “Blood-
Human-Total Protein By Refractometer (TPr)” scale (ID#108) was used and reports TP to 1 decimal place. While the in-
struments reportable range is stated to be 1.0–14.0 g/dL, instrument results down to 0.2 g/dL could be obtained and were
recorded as the displayed numerical value. All studies were conducted with the instrument and materials at room
temperature.
2.1. Specimens
Using an Institutional Review Board (IRB)-approved protocol (University of Utah IRB Protocol #0007275), previously
collected clinical serum specimens at ARUP Laboratories (Salt Lake City, UT) were obtained from frozen storage (20 °C) and
de-identified for use in method validation experiments. Serum specimens obtained from healthy donors (collected using IRB
Protocol #0007740) were also used for reference interval verification studies.
2.2. Device familiarization
Instrument familiarization studies consisted of running low (diluted Level 1) and high (Level 3) TP quality control (QC)
materials (Multiquals Liquid Unassayed; Bio-Rad Laboratories, Inc; Hercules, CA) in 10 replicates each.
2.3. Minimum volume
Minimum specimen volume parameters (60 μL) were adopted from concurrent studies validating the Palm Abbe for
urine SG [23].
2.4. Carryover
Carryover was evaluated using: a) low (diluted Level 1) and high (Level 3) QC materials (Multiquals Liquid Unassayed),
and b) patient serum pools with low and high TP. Carryover studies were conducted using the following test order: low,
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washes for subsequent serum studies.
2.5. Precision
Precision experiments were conducted over 20 days, with 2 runs daily (run ¼2 samples at each of 2 levels; each run
separated by at least 2 h) using low (diluted Level 1) and high (Level 3) QC materials (Multiquals Liquid Unassayed).
2.6. Accuracy
Accuracy experiments were conducted using residual patient serum specimens (n¼50) spanning the analytical mea-
surement range (AMR) of TP, based on prior clinical TP testing on either cobas c502 (Roche Diagnostics; Indianapolis, IN) or
Abbott ARCHICTECT ci8200 (Abbott Diagnostics; Abbott Park, IL) chemistry analyzers. Accuracy experiments were con-
ducted over 5 days (n¼10 specimens per day) on the Palm Abbe, a manual refractometer (Cat. 10414; Reichert Scientific
Instruments, Buffalo, NY), and an automated biuret chemistry assay (cobas c502; TP2, Total Protein Gen.2, Roche). Testing
was performed in duplicate on all instruments, with reverse order between duplicate runs (i.e., first run: 1,2,3,4; second run:
4,3,2,1). Testing order on the c502, however, varied based on random access instrument operation. Data are plotted as the
mean result of duplicate values. Between-method outliers (Palm Abbe versus c502, n¼1) and within-method outliers (Palm
Abbe, n¼3; c502, n¼1; manual refractometer, n¼2) as identified by StatisPro™ 2.51 (a partnership of CLSI, Wayne, PA &
Analyze-its Software, Leeds, UK) were repeated on all platforms prior to analysis. Subsequent investigation of accuracy
involved testing all 50 specimens [archived at 20 °C] by the Roche c502 glucose and triglyceride assays, as well as serum
protein electrophoresis using the CAPILLARYS PROTEIN (E) 6 kit on a CAPILLARYS 2 instrument (Sebia; Norcross, GA).
2.7. Linearity
Linearity was assessed using mixtures of either: a) high patient serum pool diluted with a low patient serum pool (final
measuring range, 4.4 g/dL–10.8 g/dL), or b) high patient serum pool spiked with bovine albumin (ALB) (AMRESCO; Dallas,
TX) diluted with a low TP pool consisting of ddH2O spiked with ALB (final measuring range, 0.3–13.9 g/dL). Bovine source
ALB was chosen due to decreased cost and similar molecular weight (66.5 kDa) to human albumin. All dilutions were
tested in triplicate. Assigned TP was based on percent-split dilution from original high and low TP pools. Percent recovery
was calculated as:
⎛
⎝⎜
⎞
⎠⎟= ×Percent Recovery
Observed Result
Assigned Result
100
Additional serial dilution studies were then conducted. These were performed using human type AB serum (Corning,
VWR; spiked with ALB to reach TP¼6.1 g/dL) diluted with either ddH2O or 0.9% sodium chloride (NaCl) (Baxter Healthcare;
Deerfield, IL). This NaCl solution contains 154 mEq/L Naþ and 154 mEq/L Cl . Pretesting of diluent solutions (ddH20 and
0.9% NaCl) on the Palm Abbe demonstrated that baseline “TP” measurements were below the instrument reportable range.
Serial dilution results were fit using linear regression while percent recovery calculations were fit automatically using non-
linear regression (Exponential Rise to Maximum, Double, 5 Parameter) with the Dynamic Curve Fit module in SigmaPlot 11
(Systat Software; San Jose, CA).
2.8. Analytical sensitivity
Analytical sensitivity was evaluated by comparing total error (TE) for seven de-identified patient serum specimens
chosen with baseline TP measurements of approximately 4, 5, and 6 g/dL. De-identified clinical specimens were divided into
two categories: a) “concordant”, Palm Abbe and c502 TP baseline results within 70.2 g/dL of each other; and b) “dis-
cordant”, Palm Abbe and c502 TP baseline results greater than 70.2 g/dL of each other. Bias for each specimen was set as
the difference between baseline Palm Abbe and Roche TP results; imprecision was determined by testing each specimen in
triplicate for three consecutive days on Palm Abbe. TE was then calculated for each specimen using the Westgard model:
TE¼ |Bias|þ2 SD. The TE(%)¼(TECbiuret mean)100. Since a published percent total allowable error TAE(%) acceptability
threshold for TP of 3.63% [24] is somewhat ambitious at low TP concentrations [the absolute TAE would approach instru-
ment resolution of 0.1 g/dL] a TAE(%) acceptability threshold of 10% was also considered.
2.9. Analytical specificity
An interference screen was conducted using low TP and high TP pools created with human AB serum (Corning, VWR)
spiked with ALB to reach TP¼6 g/dL and TP¼8 g/dL targets [25]. These pools were then spiked with conjugated bilirubin
(BILI; Scripps Laboratories), anhydrous d-glucose (GLU; VWR, Radnor, PA), lyophilized human hemoglobin (Hb; Sigma Al-
drich, St. Louis, MO), sodium chloride (NaCl; BDH Chemicals, VWR), or 20% Intralipid (Sigma Aldrich), with spiked-
Table 1
Imprecision.
Material Mean TP material (g/dL) Total imprecision (SD) Total imprecision (%CV) Within run (SD) Between run (SD) Between day (SD)
Low QC 2.35 0.05 2.2 0.02 0.00 0.05
High QC 10.64 0.05 0.5 0.04 0.02 0.02
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form [23]. 5 aliquots were tested per interferent in alternating order of control and test specimens. Interference was sug-
gested when results exceeded a TAE of 3.63% [24]. Characterization of identified interferences were then evaluated through
dilution mixtures of low and high interferent concentrations dissolved in a 6 g/dL TP pool (tested with 5 replicates in
alternating ascending and descending order). The level of significant interference was defined as the concentration (based
on linear fit) where the upper 95% confidence limit for bias exceeded TAE of 3.63% [24].
2.10. Reference intervals (RIs)
The laboratory's previously established RIs for TP (female and male: 6.3–8.2 g/dL) were evaluated using 20 female and 20
male serum samples obtained from healthy donors.
2.11. Data analysis
Data was analyzed using EP Evaluators 10 (Data Innovations; South Burlington, VT), StatisPro™ 2.51, Microsoft Excel
2010 (Redmond, WA), and SigmaPlot 11 (Systat). Graphs were prepared using SigmaPlot. Data is presented as mean7-
standard deviation (SD) unless otherwise indicated.3. Results
Familiarization studies demonstrated that the Palm Abbe digital refractometer was easy to operate, a finding that was
consistent with our companion study evaluating the device for urine SG measurement [23]. Carryover studies using low TP
(2.4 g/dL) and high TP (10.7 g/dL) QC material - without ddH2O washes between measurements - demonstrated an un-
acceptable specimen carryover of 8.5%. Carryover using QC material was eliminated with the introduction of single in
between ddH2O wash steps (carryover 0.0%). Using low TP (4.4 g/dL) and high TP (10.6 g/dL) patient pools with in between
ddH2O wash steps, minimal carryover (o2%) was observed.
Results from precision experiments over 20 days are presented in Table 1. Low total imprecision was demonstrated using
both low QC (%CV, 2.2; mean TP 2.35 g/dL) and high QC (%CV, 0.5; mean TP 10.64 g/dL) material. Overall precision estimates
(SD) met the manufacturer claims (70.1 g/dL) [26].
Accuracy was assessed by comparing Palm Abbe results to a manual refractometer (Fig. 1A–C) and a biuret method on a
Roche cobas c502 chemistry analyzer (Fig. 1D–F). Open (white) symbols indicate specimens in which a monoclonal protein
was identified by serum protein electrophoresis. A correlation to both manual refractometry (Deming regression,
y¼1.092x0.907, r¼0.992) and the Roche TP chemistry assay (Deming regression, y¼0.989xþ0.431, r¼0.976) was ob-
served. A negative bias was noted at lower concentration of TP versus manual refractometry (absolute bias, 0.22 g/dL,
Fig. 1B; percent bias, 3.03%, Fig. 1C). An overall positive bias (absolute bias,þ0.35 g/dL, Fig. 1E; percent bias, þ5.01%,
Fig. 1F) was observed versus the Roche chemistry assay.
The gray symbols shown in Fig. 1D–F indicate “outlier” specimens that had both a 40.9 g/dL absolute bias (Fig. 1D) and
412% percent bias (Fig. 1E) in Palm Abbe versus Roche biuret TP results. To determine whether non-protein solutes may
contribute to this bias, all 50 specimens used in the accuracy studies (7 outliers, 43 non-outliers) were tested for triglyceride
and glucose concentration. There was a clear increase in triglycerides in outliers (513.17577.5 mg/dL, range 142–1803 mg/
dL) versus non-outliers (123.4765.2 mg/dL, range 49–311 mg/dL, po0.01). Furthermore 86% of outliers (6 of 7), but only
11.6% of non-outliers (5 of 43) had triglyceride concentrations 4200 mg/dL. There was a potential (but non-significant)
trend toward increased glucose in outliers (152.6757.8 mg/dL, range 97–250 mg/dL) versus non-outliers (116.2749.9 mg/
dL, range 67–298 mg/dL, p¼0.09). No outliers had a monoclonal protein.
Linearity was evaluated using mixtures of: a) low and high concentration patient pools (Fig. 2A,B; TP range tested, 4.4–
10.8 g/dL; slope 1.009), and b) low TP pool (ddH2O spiked with ALB) and high concentration patient pool spiked with ALB
(TP range tested, 1.7–13.9 g/dL; slope 0.950; Fig. 2C,D). Linear regressions are shown in Fig. 2 A,C, while percent recovery for
corresponding data is shown in Fig. 2 B,D. While instrument linearity was verified using both strategies, a trend toward
decreased recovery was observed when using ALB-spiked ddH2O matrix as a diluent at lower TP concentrations (Fig. 2D).
Serial dilution studies were then conducted using a 6.1 g/dL baseline pool (human AB serum matrix adjusted with bovine
ALB) with either ddH2O or 0.9% NaCl diluents (Fig. 3). Decreased recovery was observed using ddH2O diluent (Fig. 3A, black
circles; linear regression, y¼1.223x1.357, r¼0.999; Fig. 3A). Markedly decreased percent recovery was observed with
Fig. 1. Accuracy. Comparison of Palm Abbe versus manual refractometry (A-C) or Roche c502 (D-F) TP results. Solid line is unity; dotted line is Deming regression (A, D). B. Absolute bias (in g/dL) of Palm Abbe
versus manual refractometry. E. Absolute bias (in g/dL) of Palm Abbe versus Roche c502. Solid line is zero bias reference; dotted line is absolute bias (B, E). C. Percent bias of Palm Abbe versus manual refractometry.
F. Percent bias of Palm Abbe versus Roche c502. Solid line is zero bias reference; dotted line is percent bias (C, F). Open white symbols (all panels) indicate serum specimens which contain a monoclonal protein.
Gray symbols (D-F only) indicate “outlier” serum specimens (described in Section 3. Results) where absolute bias (E) is 40.9 g/dL and percent bias (F) is 412%, when comparing Palm Abbe to the Roche biuret
method.
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Fig. 2. Linearity. Linearity results plotted for (A) high patient TP pools diluted with low patient TP pools or (C) high patient TP pools diluted with low
concentration ALB-spiked ddH20. Data plotted in A, C are averages 7 SD for each dilution. Error bars in A, C are hidden behind data points; too small to
visualize. Solid lines (A, C) indicate unity; dotted lines are linear regression (hidden behind unity in A). B, D. Raw results for percent recovery (n¼3
measurements per concentration, largely overlapping). Percent recovery shown in B corresponds to the linearity experiment in A. Percent recovery shown
in D corresponds to the linearity experiment in C. Dashed lines (in B, D) show 100% recovery and 73.63% TAE.
J.J.H. Hunsaker et al. / Practical Laboratory Medicine 6 (2016) 14–24 19additional dilutions (Fig. 3B; nonlinear regression, r¼0.999). To confirm that this decreased recovery was due to concurrent
dilution of non-protein solutes, partially solute replete diluent (0.9% NaCl) was then used (Fig. 3A, B; open circles). As
predicted, this improved the apparent overall recovery of TP as shown in Fig. 3A (open circles; linear regression,
y¼1.095x0.583, r¼0.999) and Fig. 3B (open circles, nonlinear regression, r¼0.998). Palm Abbe TP measurements were
significantly different between corresponding ddH2O and NaCl dilutions (po0.001; paired t-test of average results across
each dilution).
Analytical sensitivity was evaluated by calculating TE for seven de-identified patient specimens chosen for baseline TP
measurements of approximately 4, 5, and 6 g/dL (Table 2). As shown in Table 2, bias was a major contributor to TE. For
example, in the three “discordant” specimens (based on c502 to Palm Abbe baseline TP differences greater than 70.2 g/dL
of each other), none of the specimens fell within a TAE(%)of 3.63%. At a TAE(%) of 10%, TE(%) for “discordant” specimens was
either just above (Specimens E and F) or below (Specimen G) the acceptable threshold. Two of the four “concordant”
Fig. 3. Serial Dilutions. A. Palm Abbe results plotted for serial dilutions of a human serum pool into ddH2O () or 0.9% NaCl (○). Dotted line is unity; solid
lines are linear regression. Data plotted in are averages 7 SD for each dilution (n¼5; error bars too small to visualize at most points). B. Results plotted as
percent recovery. Dashed line is 100% recovery. Solid lines are non-linear regression (see 2.7. Linearity in Section 2. Methods). Data plotted in are averages
7 SD for each dilution (n¼5; error bars too small to visualize at some points).
Table 2
Analytical Sensitivity.
TP c502 (g/dL) TP Palm Abbe (g/dL) Bias (g/dL) Imprecision (SD; g/dL) TE (g/dL) TE (%)
Concordant
Specimen A 3.9 4.1 0.2 0.05 0.30 7.7a
Specimen B 4.2 4.4 0.2 0.00 0.20 4.8a
Specimen C 5.3 5.3 0 0.03 0.07 1.3
Specimen D 6.2 6.1 0.1 0.05 0.21 3.3
Discordant
Specimen E 4.2 4.6 0.4 0.03 0.47 11.1a,b
Specimen F 5.2 5.6 0.4 0.07 0.53 10.3a,b
Specimen G 6.3 6.7 0.4 0.05 0.50 7.9a
a TE%43.63.
b TE%410.
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of 3.63%, while all met the threshold of 10%.
Analytical specificity was then evaluated by conducting an interference screen to look for potential endogenous substances (total
dissolved solutes) that may affect TP measurement. GLU and Intralipid demonstrated the potential for TP interference at the screen
concentrations tested (Table 3). Hb, BILI, and NaCl did not show significant interference (TE 43.63%) at described concentrations.
Further characterization of interference for GLU and Intralipid was conducted using the dose-response series of interferent mixtures
dissolved in a 6 g/dL serum TP matrix (Fig. 4). Significant interference was observed at high concentrations of GLU (4267mg/dL;
Fig. 4A) and triglycerides (TRIG,4580mg/dL, Fig. 4B; corresponding Roche lipemia “L” index of 4257, Fig. 4C).
Our current laboratory adult reference intervals for TP (6.3–8.2 g/dL) were verified on the Palm Abbe refractometer using
male (n¼20) and female (n¼20) specimens according to a CLSI EP28-A3c protocol for validation of transference (data not
shown) [27].
Table 3
Interference screen.
Interferent Interferent Concentration TP (g/dL) Bias (g/dL) % Difference
Hb 0.2 g/dL 6 þ0.14 2.3%
0.2 g/dL 8 þ0.16 2.0%
BILI 15.9 mg/dL 6 þ0.06 1.0%
18.7 mg/dL 8 þ0.02 0.2%
Lipemia (Intralipid) Trig. 3829 mg/dL (L index 1647) 6 þ1.06 17.7%
Trig. 3810 mg/dL (L index 1622) 8 þ0.84 10.4%
NaCl Na 177 mmol/L; Cl 137 mmol/L 6 þ0.20 3.3%
Na 184 mmol/L; Cl 143 mmol/L 8 þ0.20 2.5%
GLU 1024 mg/dL 6 þ0.70 11.7%
1015 mg/dL 8 þ0.68 8.4%
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The present experiments demonstrate the analytical performance of a handheld digital refractometer for TP measure-
ment. Overall precision was near the literature-described precision claims for TP by refractometry (71% [6] and o2% [8]).
Palm Abbe precision was similar to the performance data described for biuret methods. For example, intermediate (be-
tween-day) precision for TP on Roche c501/502 analyzers has been described as 1.7–2.5%CV [28]. An analytical performance
characterization noted inter-assay precision on the Roche c701 TP assay to be 1.7–2.1%CV (for QC) and 1.5–2.4%CV (for
serum) [29].
While correlation was observed between Palm Abbe, manual refractometry, and biuret results (Fig. 1), a fair amount of
scatter was present and may reflect between-patient variability in non-protein solutes. The slight positive bias (Palm Abbe
vs. biuret) may reflect different standardization/calibration of platforms. Given the observed bias, it is likely that published
accuracy claims for TP by refractometry (70.1 g/dL) [6] could only be met using relatively purified solutions of TP (i.e. non-
clinical materials). Additionally, the observed bias (Palm Abbe vs. biuret) does exceed published desirable inaccuracy spe-
cifications (1.36%) [24]. It should be noted, however, that the clinical significance of TP differences at these inaccuracy
specifications is negligible. Trueness of a Roche biuret TP assay (c701; within desirable bias limits of 1.2%) has previously
been described [29].
While assay linearity was verified (Fig. 2A,C), a decreased percent recovery was observed using ddH2O-matrix diluent at
low concentrations (Fig. 2D). This finding was confirmed in separate serial-dilution studies (Fig. 3). Decreased percent
recovery with ddH2O dilution is expected, however, as it is concurrent with dilution of non-protein solutes that also con-
tribute to solution density. As confirmation of this, improved recovery was observed when using a partially solute-replete
diluent (0.9% NaCl; Fig. 3A, B). Linearity on our comparative Roche biuret method (c502) was verified during our initial
instrument validations (slope 1.001; data not shown). Linearity on the c502 TP assay is consistent with that observed in a
separate, comprehensive analytical performance evaluation of the cobas 8000 system [29].
Individual specimen TP differences observed between refractometry and the biuret method (Fig. 1) may have several
causes. Specimens were mixed thoroughly prior to testing, thus we do not believe that sample heterogeneity due to in-
adequate mixing contributed to scatter. Furthermore, the relatively tight correlation between Palm Abbe and manual re-
fractometry results (Fig. 1A) argues against inadequate mixing and suggests that the presence of additional, non-protein
solutes may contribute to differences versus biuret measurements. Indeed, the 7 discordant “outlier” specimens (Fig. 1D–F)
had higher average triglyceride concentrations than the remaining 43 non-outlier specimens used in the accuracy study.
Interference studies (Fig. 4) reinforce the fact that high concentrations of non-protein solutes (e.g. GLU and/or lipids) can
contribute to elevation in “TP” measurements beyond the established TAE. Concentrations of these solutes may fluctuate
over time within individual patients. This concern argues against the use of refractometry for TP measurement when a
biuret alternative is available. Accuracy of TP measurements (Palm Abbe versus biuret) were similar in specimens with and
without monoclonal proteins.
It has been stated that the use of refractometry for measurement of TP in low concentrations (e.g. o3.5 g/dL) is inad-
visable [8]. At these lower TP concentrations non-protein solutes have a greater relative contribution to solution density
than in normal serum used to calibrate the refractometer scale. Such low TP concentrations in serum or plasma are ex-
ceedingly rare, making up less than 0.15% of clinical specimens at our facility (data not shown). It is also likely that some of
these specimens represent IV-line contamination and inadvertent dilution. Using the overall approximate bias shown in
accuracy studies (0.35 g/dL; Fig. 1D) and an imprecision of 0.05 g/dL (based on Tables 1,2), a TE of 0.45 g/dL can be calcu-
lated. Since this TE would be 410% of any measured serum TP concentrations o4.5 g/dL, we have estimated a lower limit of
the measuring interval of 4.5 g/dL. Analytical sensitivity studies, however, show that variation in TE exists across specimens
and TP concentrations (Table 2). Ultimately, bias represented a greater contribution to TE than did imprecision.
While it has been argued in the veterinary literature that refractometry can be used for low TP body fluid testing (at or
Fig. 4. Interference Studies. Effect of increasing concentration of (A) GLU, (B) TRIG, or (C) Roche lipemic index (“L”) on Palm Abbe TP results. Solid black line, linear regression; solid gray line, upper 95% confidence
interval of linear fit; dotted black line, limit of allowable bias (3.63%) from baseline TP concentration; dashed gray line, intercept where upper 95% confidence exceeds allowable bias.
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J.J.H. Hunsaker et al. / Practical Laboratory Medicine 6 (2016) 14–24 23below 2–2.5 g/dL) [30,31], studies in human pleural fluid demonstrated a risk for erroneous readings [32]. Given that body
fluids may contain dramatic differences in both protein and non-protein solutes (e.g. electrolytes, GLU, Hb, hyaluronic acid,
lipids, etc), we concur that refractometry is not appropriate for routine clinical body fluid TP measurement.
While TP specimen results (between biuret and refractometry) are similar on CAP Electrophoresis PT surveys in terms of
mean, SD, and %CV [12], the matrix of PT material may not completely reflect the complexity of fresh serum and plasma
specimens. The nature of PT testing also does not embody between-patient biological variability that is expected in other
non-protein analytes.
In conclusion, while the digital refractometer used in the present report demonstrated excellent precision, it did not
introduce benefits in accuracy over manual refractometry in regards to potential interference due to non-protein solutes.
Additionally, refractometry is vulnerable to bias at low TP concentrations. While some clinical laboratory settings may
benefit from TP measurement by refractometry (particularly low-resource settings as there is negligible cost of operation),
its use should be discouraged where alternate biuret methods are readily available.Conflicts of interest
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